Table 3 The detailed subgroup analysis results of clinicopathological parameters

Age > 50 vs. ≤ 50 (OR)

0.867[0.699,1.076]; I2 = 66.3 %; z = 1.30; p = 0.195

0.855[0.562,1.303]; I2 = 89.8 %; z = 0.73; p = 0.466

_

0.804[0.669,0.965 ]; I2 = 0.0 %; z = 2.35; p = 0.019

1.081[0.894,1.307 ]; I2 = 0.0 % ; z = 0.81 ; p = 0.420

0.731[0.592, 0.901]; I2 = 55.6 %; z = 2.93 ; p = 0.003

Tumour size > 2 cm vs. ≤ 2 cm (OR)

1.151[0.997,1.329]; I2 = 25.0 %; z = 1.92 ; p = 0.055

1.098[0.966,1.247]; I2 = 0.0 %; z = 1.43; p = 0.151

_

1.268[0.954,1.686 ]; I2 = 37.0 %; z = 1.64 ; p = 0.101

1.296[0.867,1.935 ]; I2 = 54.9 %; z = 1.26 ; p = 0.206

1.146[1.016 , 1.293]; I2 = 0.0 %; z = 2.22; p =0.026

LN(+) vs. LN(−)(OR)

1.305[1.071 ,1.590]; I2 = 60.0 %; z = 2.64; p =0.008

1.121[0.953 ,1.318]; I2 = 38.4 %; z = 1.37; p = 0.169

2.917[1.067 ,7.971]; I2 = .%; z = 2.09; p = 0.037

1.590[1.057 ,2.394]; I2 = 65.9 %; z = 2.22; p = 0.026

1.636[0.993 ,2.693]; I2 = 71.2 % ; z = 1.93; p =0.053

1.209[1.017 ,1.437 ]; I2 = 41.6 %; z = 2.16; p =0.031

pT:T3/T4 vs.T1/T2 (OR)

0.990[0.748 ,1.310]; I2 = 0.0 % ; z = 0.07; p =0.943

0.990[0.748 ,1.310]; I2 = 0.0 % ; z = 0.07; p = 0.943

_

_

_

0.990[0.748 ,1.310]; I2 = 0.0 % ; z = 0.07; p = 0.943

StageIII/IV vs.I/II (OR)

1.115[0.631 ,1.970 ]; I2 = 68.7 %; z = 0.37; p =0.709

0.925[0.642 ,1.335]; I2 = 30.7 %; z = 0.41; p = 0.679

_

_

1.181[0.418,3.341 ]; I2 = 79.1 %; z = 0.31; p =0.754

_

Histological grade:III vs.I(OR)

3.769[2.596, 5.472]; I2 = 64.6 %; z = 6.98; p < 0.0001

3.360[1.774, 6.363]; I2 = 79.0 %; z = 3.72; p < 0.0001

_

4.298[3.221, 5.736]; I2 = 0.0 %; z = 9.88; p < 0.0001

6.248[3.627,10.763]; I2 = .%; z = 6.60; p < 0.0001

3.342[2.270, 4.920]; I2 = 60.0 % ; z = 6.11; p < 0.0001

III vs. II (OR)

2.299[1.719,3.075]; I2 = 80.3 %; z = 5.61; p < 0.0001

1.945[1.551,2.439]; I2 = 56.9 %; z = 5.76; p < 0.0001

_

3.422[2.706,4.326]; I2 = 0.0 %; z = 10.29; p < 0.0001

2.287[1.740,3.005]; I2 = .%; z = 5.94; p < 0.0001

2.304[1.561, 3.400]; I2 = 85.2 % ; z = 4.20; p < 0.0001

II vs. I (OR)

1.596[1.172,2.174]; I2 = 51.3 %; z = 2.97; p = 0.003

1.790[1.191,2.691]; I2 = 51.2 %; z = 2.80; p = 0.005

_

1.260[0.947,1.677]; I2 = 18.7 %; z = 1.37; p = 0.171

2.732[1.636,4.562]; I2 = .%; z = 3.84; p < 0.0001

1.351 [1.087, 1.680]; I2 = 0.0 % ; z = 2.64 ; p = 0.008

Lymphatic invasion (+) vs.(−) (OR)

1.382[0.844,2.262]; I2 = 42.8 %; z = 1.29; p = 0.198

_

_

_

2.071[1.045,4.102]; I2 = 0.0 %; z = 2.09; p = 0.037

_

Vessel invasion (+) vs.(−) (OR)

1.107[0.750,1.634]; I2 = 24.0 %; z = 0.51; p = 0.608

_

_

1.107[0.750,1.634]; I2 = 24.0 %; z = 0.51; p = 0.608

_

_

ER (+) vs.(−) (OR)

0.435[0.287,0.660]; I2 = 90.3 %; z = 3.91; p < 0.0001

0.571[0.276,1.181]; I2 = 95.7 %; z = 1.51; p = 0.131

_

0.347[0.252,0.478]; I2 = 31.7 %; z = 6.48; p < 0.0001

0.419[0.193,0.908]; I2 = 88.8 %; z = 2.21; p = 0.027

0.481[0.324,0.714]; I2 = 84.8 %; z = 3.63; p < 0.0001

PR (+) vs.(−) (OR)

0.493[0.296,0.822]; I2 = 89.9 %; z = 2.71; p = 0.007

0.417[0.128,1.357]; I2 = 96.8 %; z = 1.45; p = 0.146

_

0.501[0.405,0.621]; I2 = 0.0 %; z = 6.31; p < 0.0001

0.432[0.195,0.959]; I2 = 85.1 %; z = 2.06; p = 0.039

0.594[0.373,0.945]; I2 = 79.2 %; z = 2.20; p = 0.028

HER2 (+) vs.(−) (OR)

1.896[1.335,2.692]; I2 = 75.1 %; z = 3.58; p < 0.0001

1.141[0.718,1.814]; I2 = 81.6 %; z = 0.56; p = 0.576

2.299[1.066,4.960]; I2 = .%; z = 2.12; p = 0.034

3.651[2.638,5.052]; I2 = 0.0 %; z = 7.81; p < 0.0001

1.684[0.881,3.218]; I2 = 74.4 %; z = 1.58; p = 0.115

2.059[1.203,3.523]; I2 = 81.0 %; z = 2.64; p = 0.008

Molecular Subtypes :TNBC vs. nTNBC (OR)

2.456[1.801,3.348]; I2 = 11.3 %; z = 5.68; p < 0.0001

3.514[1.563,7.901]; I2 = .%; z = 3.04; p = 0.002

_

2.342[1.625,3.375]; I2 = 17.5 %; z = 4.57; p < 0.0001

2.990[1.666,5.366]; I2 = 24.6 %; z = 3.67; p < 0.0001

2.230[1.642,3.029]; I2 = .%; z = 5.14; p < 0.0001

Luminal A vs. Luminal B vs. Luminal HER2 vs. HER2-enriched vs. Basal-like

_

p < 0.0001

_

p < 0.0001

p < 0.0001

_